Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prostaglandin and beraprost sequential therapy in type 2 diabetes with abnormal ABI without typical intermittent claudication
ChiCTR1800017817Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jun 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Vasostenoon and beraprost in lower extremity arterial disease (LEAD), type 2 diabetes mellitus (T2DM) and diabetic polyneuropathy (DPN) (2 arms), sponsored by Peking University First Hospital. Primary endpoints: Six-minute walking test, Questionnaires and 3 more. Planned start Jun 2018; status: not yet recruiting.
02
Drugs
Vasostenoonberaprost
03
Conditions
lower extremity arterial disease (LEAD)type 2 diabetes mellitus (T2DM)diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on ChiCTR1800017817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017817.